510(k) device
Rapid2 Therapy System
Magstim Company, Ltd. · Transcranial Magnetic Stimulator (OBP, Class II) · First FDA decision Mar 10, 2017, newest Mar 10, 2017DepressionOCD, PTSD and other psychiatric conditions
Last checked: Nov 19, 2026Source: FDA, CMS, ClinicalTrials.gov, PubMed
FDA decisions
1
510(k) pathway
Device trials
95
Naming "Rapid2 Therapy"
MAUDE reports
0
Brand "Rapid2 Therapy", since 2015
PubMed studies
0
Mentioning "Rapid2 Therapy"
AI summary across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, MAUDE and PubMed data on this page, plus web searches for payment facts.
Product review deck
A slide deck reviewing Rapid2 Therapy System
About ten slides on the technology, clinical evidence, regulatory history and commercialization, built with AI from the data on this page and web research, with sources. Download it as PowerPoint to edit or as PDF to share.
- Executive summary and key facts
- Technology
- Clinical evidence and trials
- Regulatory history and safety
- Reimbursement, market and competition
- Risks, outlook and sources
AI-written from public data and may contain mistakes. Check each fact against its source before relying on it. Not investment, legal, reimbursement or medical advice.
FDA decisions
The newest 1 of 1 decisions filed under this name.
- Rapid2 Therapy System510(k)
K162935 · Decided Mar 10, 2017 · 141 days after receipt
Device type: Transcranial Magnetic Stimulator (OBP) · Neurology & Neurosurgery
Medicare coverage
National and local coverage documents whose titles match this device or its device type. Payment add-ons (NTAP, pass-through, TCET) and likely codes are covered in the summary above.
- Transcranial Magnetic StimulationLocal determinationIn effectL33398Wellpoint FederalUpdated Jul 16, 2026
- Transcranial Magnetic StimulationProposed local determinationProposedDL33398National Government Services, Inc.Updated Mar 27, 2026
- Transcranial Magnetic Stimulation (TMS)Local determinationIn effectL34641WPS Insurance CorporationUpdated Mar 20, 2026
- Transcranial Magnetic Stimulation (TMS)Local determinationIn effectL37086Noridian Healthcare Solutions, LLCUpdated Aug 6, 2025
- Repetitive Transcranial Magnetic Stimulation (rTMS) in AdultsLocal determinationIn effectL34869Palmetto GBAUpdated Jan 7, 2025
- Transcranial Magnetic Stimulation (TMS)Local determinationIn effectL36469CGS Administrators, LLCUpdated May 30, 2024
- Transcranial Magnetic Stimulation (TMS) in the Treatment of Adults with Major Depressive DisorderLocal determinationIn effectL34522First Coast Service Options, Inc.Updated Oct 21, 2022
- Transcranial Magnetic Stimulation (TMS) in the Treatment of Adults with Major Depressive DisorderLocal determinationIn effectL34998Novitas Solutions, Inc.Updated Oct 21, 2022
Clinical trials
Device studies on ClinicalTrials.gov that name "Rapid2 Therapy", any status and sponsor, newest update first.
The Methodist Hospital Research InstituteAcademic, hospital or other
NCT07948330 · 23 participants (planned) · Start Sep 16, 2026 · Primary completion Oct 1, 2027
Device: Magstim - rTMS system · For: Urinary Incontinence; Prostate Treatment; Incontinence After Prostate Treatment
Sites: Houston, Texas
Oregon Health and Science UniversityAcademic, hospital or other
NCT03470480 · 50 participants (planned) · Start Feb 7, 2018 · Primary completion Sep 1, 2027
Device: Real Repetitive transcranial magnetic stimulation; Sham Repetitive transcranial magnetic stimulation · For: Methamphetamine Abuse; Substance Use Disorders; Stimulant Dependence and 3 more
Sites: Portland, Oregon
Ege UniversityAcademic, hospital or other
NCT06926270 · 28 participants · Start Oct 1, 2024 · Primary completion Jun 20, 2025
Device: Repetitive transcranial magnetic stimulation (rTMS) · For: Postpolio Syndrome
Sites: Izmir, Turkey (Türkiye)
92 more trials with a free account
Adverse event reports (MAUDE)
Reports received since 2015 naming the brand "Rapid2 Therapy", and for the whole product code for context.
This brand
0 reports: 0 malfunction, 0 injury, 0 death
Whole product code OBP
337 reports: 9 malfunction, 323 injury, 2 death
Newest reports for this brand
No MAUDE reports name this brand.
Recalls
From FDA's recall database. FDA lists each recalled product separately, so one recall can appear several times. A recall is often a correction or a labeling change, not a removal from the market.
Z-1965-2020 · Started Mar 23, 2020
Reason given: It was identified that there is a potential for the Stim Interconnecting high Voltage Cable located at the rear of the Rapid2 and Horizon power supply unit to fail.
Cause as FDA categorized it: Nonconforming Material/Component · Device type: Transcranial Magnetic Stimulator (OBP)
Z-1966-2020 · Started Mar 23, 2020
Reason given: It was identified that there is a potential for the Stim Interconnecting high Voltage Cable located at the rear of the Rapid2 and Horizon power supply unit to fail.
Cause as FDA categorized it: Nonconforming Material/Component · Device type: Transcranial Magnetic Stimulator (OBP)
Z-1352-2018 · Started Sep 28, 2017
Reason given: Users manuals not supplied with 4800-00T US Rapid Therapy System
Cause as FDA categorized it: Employee error · Device type: Transcranial Magnetic Stimulator (OBP)
Published research
The most relevant PubMed records for "Rapid2 Therapy"[tiab]. The summary above synthesizes these.
No PubMed record mentions this device by name.
Other devices of this type
Also filed under product code OBP.
- NeuroStar TMS Therapy SystemNeuronetics, Inc. · 510(k) 2022
- BrainsWay Deep TMS SystemBrainsway , Ltd. · 510(k) 2025
- Apollo TMS Therapy SystemMag & More GmbH · 510(k) 2026
- MagVita TMS Therapy w/MagPro R20Tonica Elektronik A/S · 510(k) 2017
- NeuroStar Advanced Therapy System (All previously cleared models)Neuronetics, Inc. · 510(k) 2024
- Magstim Horizon 3.0 TMS Therapy SystemMagstim Company, Ltd. · 510(k) 2023
- HORIZON TMS Therapy System with NavigationMagstim Company, Ltd. · 510(k) 2019
- Nexstim Navigated Brain Stimulation (NBS) 6 System (NBS6)Nexstim Oyj · 510(k) 2026
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.